PA-RELIEF-THERAPEUTICS
29.7.2020 07:32:11 CEST | Business Wire | Press release
RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTC:RLFTF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that FDA has granted an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.1
The expanded access protocol may be viewed on www.clinicaltrials.gov NCT04453839. Physicians who wish to enroll their patients in the protocol must submit the protocol to their local investigational review board and file FDA form 1572 with NeuroRx, Inc. Further information may be obtained from expandedaccess@neurorxpharma.com .
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial .”
The SARS-CoV-2 coronavirus that causes COVID-19 attacks the body by entering the small population of Alveolar Type II cells in the lung.2 Without Type II cells, the lung cannot transmit oxygen, which why the coronavirus causes acute respiratory failure. 50 years of scientific research demonstrates that VIP binds specifically to the Type II cell and protects that cell against cytokines (inflammatory molecules) and a wide array of toxic and infectious injuries.”3
About RELIEF THERAPEUTICS Holding AG
The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent4 for RLF-100 and proprietary manufacturing processes for its synthesis.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF (ISIN: CH0100191136).
About NeuroRx, Inc.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials.
Disclaimer : This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
1 Youssef JG, Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide doi: 10.20944/preprints202007.0178.v1
2 Mason R. Pathogenesis of COVID-19 from a Cell Biologic Perspective. Eur Respir J. April 9 Epub ahead of print. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144II60/
4 US 8,178,489 Formulation for Aviptadil
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ScottsMiracle-Gro Cultivates End-to-End Supply Chain Agility with Kinaxis22.6.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ unifies planning to drive faster decisions and stronger results across a complex North American network Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that ScottsMiracle-Gro, the leading marketer of branded consumer lawn and garden products in North America, is expanding its partnership with Kinaxis. The move will further optimize its supply chain planning operations as part of a broader transformation initiative, building on proven success and results achieved in recent years. Operating in a seasonal environment, where demand can be impacted by regional weather patterns, retailer promotions, and shifting consumer behavior, ScottsMiracle-Gro is investing further in the Kinaxis Maestro™ platform to improve planning accuracy and strengthen end-to-end supply chain orchestration across its North American network. This transformation reflects the company’s focus on supply chain technology as a foundational necessi
NIQ Expands GeoPurchase Audiences Globally, Unlocking Growth Opportunities for Marketers in Poland, Belgium, Mexico, and Indonesia22.6.2026 12:00:00 CEST | Press release
International expansion helps advertisers target audiences based on local consumer demand NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its GeoPurchase audiences into Poland, Belgium, Mexico, and Indonesia, extending its purchase-based, geo-targeted audiences to new international markets. As privacy regulations tighten and identifiers like cookies decline, marketers need new ways to reach high-value consumers at scale. NIQ’s GeoPurchase Audiences address this challenge by helping marketers identify and target consumers based on demand, not just demographics. GeoPurchase audiences help marketers pinpoint geographic areas where consumers are most likely to purchase specific FMCG categories, brands, or sub-brands, so media investments can concentrate where retail opportunities are strongest. By focusing investments in priority locations, marketers can connect with the audiences that matter in the markets with the greatest opportunity. As a resu
Smartly Introduces Smartly Synapse, the Intelligent AI Orchestration Layer Powering Its Advertising Platform22.6.2026 12:00:00 CEST | Press release
Smartly Synapse powers Smartly’s agentic orchestration, providing marketers a faster, more intelligent way to plan, execute, and optimize millions of signals for better results Smartly today introduced Smartly Synapse, the intelligent AI orchestration and memory layer behind every Smartly AI Agent. Built on years of cross-channel creative, media and performance intelligence and continuously shaped by real-world outcomes, Smartly Synapse transforms millions of signals into actions that help marketers plan smarter, execute faster and drive stronger business results. Smartly Synapse creates a continuous performance loop where marketer intent, business context, campaign activity and outcomes continuously inform one another. Its shared intelligence and memory layer helps the system learn from every campaign, improving future recommendations, execution and performance. “Smartly Synapse is the intelligent AI orchestration and memory layer behind our AI agents. It augments Smartly’s existing p
Europe’s Original First Check Investor Seedcamp Raises $320 Million22.6.2026 11:23:00 CEST | Press release
First backer of Revolut, Wise, UiPath, Synthesia and Fluidstack brings nearly two decades of experience and conviction to Europe’s next frontier Expands US team to support founders building global giants from day one Raise is split across a $220m Core fund and $100m Select fund to back winners through Series B and beyond Backing founders at the very beginning - before the company or the theme is obvious Seedcamp, Europe’s original first check investor and earliest backer of companies including Revolut, Wise, UiPath, Synthesia and Fluidstack, has raised $320 million to invest in the next generation of global companies. US expansion for born global founders and early growth capital for portfolio winners Since launching in 2007 with a $2.5m first fund, Seedcamp now manages over $1bn in AUM and has delivered some of the strongest venture fund returns in Europe. Seedcamp Fund III has now returned over 13x DPI to its Limited Partners, and Fund IV sits at over 5x net TVPI. The new capital is
Navan Invests in European Footprint with New Partnerships22.6.2026 10:01:00 CEST | Press release
New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced new integrations with European travel suppliers. Navan will add to its platform a direct New Distribution Capability (NDC) connection with Italy’s national air carrier, ITA Airways; overnight rail services in the UK with Caledonian Sleeper; and mobile-first car rental bookings in France with Virtuo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622904121/en/ New integrations with ITA Airways, Caledonian Sleeper, and Virtuo elevate localized inventory across Europe “We’re seeing incredible momentum across Europe, bookings to and from the continent are up year-over-year, and to truly serve the European market you have to continually invest locally,” said Michael Riegel, Chief Customer Officer at Navan. “By bringing ITA’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom